This is pointed out in our research which appears in the peer-reviewed journal Cogent Medicine
This surge in obesity rates has led to an increase in related comorbidities such as type 2 diabetes, hypertension, and cardiovascular diseases, escalating healthcare costs
Tirzepatide, a dual GIP/GLP-1 receptor agonist, is also available in oral and sublingual compounded formats
Studies published before 2013, non-English language articles, and case reports were excluded
with documented symptomatic hypoglycemia occurred in 17.3% and 24.4% of patients when semaglutide 0.5 mg and 1 mg, respectively
Tracking your response objectively, through weight measurements, appetite scores, and blood glucose monitoring, helps separate real pharmacological differences from the anxiety of change